跳至主要内容
临床试验/NCT01881126
NCT01881126已完成4 期

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Allergan0 个研究点目标入组 93 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Allergan
入组人数
93
主要终点
Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM

研究概览

简要总结

This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ocular hypertension or glaucoma that requires treatment with medication
  • Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

排除标准

  • History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
  • History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
  • Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study

研究组 & 干预措施

bimatoprost 0.01% and hypromellose 0.3%

Active Comparator

Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.

干预措施: bimatoprost 0.01% (Drug)

bimatoprost 0.01% and hypromellose 0.3%

Active Comparator

Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.

干预措施: hypromellose 0.3% (Drug)

travatan 0.004% and timolol 0.5%

Active Comparator

Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.

干预措施: travatan 0.004% (Drug)

travatan 0.004% and timolol 0.5%

Active Comparator

Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.

干预措施: timolol 0.5% (Drug)

结局指标

主要结局

Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM

时间窗: Week 12 at 8 AM, 12 PM, and 4 PM

IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM. IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.

次要结局

未报告次要终点

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验